Artículos por temáticas

Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington's disease.

Kong G, Cao KL, Judd LM, Li S, Renoir T, Hannan AJ.

Neurobiol Dis. 2020 Feb;135:104268. doi: 10.1016/j.nbd.2018.09.001. Epub 2018 Sep 5.

Predictors of simulated driving performance in Huntington's disease.

Jacobs M, Hart EP, Mejia Miranda Y, Groeneveld GJ, van Gerven JMA, Roos RAC.

Parkinsonism Relat Disord. 2018 Oct 1. pii: S1353-8020(18)30433-4. doi: 10.1016/j.parkreldis.2018.10.002. [Epub ahead of print]

Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan.

Kielar C, Jennifer Morton A.

J Huntingtons Dis. 2018;7(1):61-76. doi: 10.3233/JHD-170265.

Social Cognition and Oxytocin in Huntington's Disease: New Insights.

Unti E, Mazzucchi S, Frosini D, Pagni C, Tognoni G, Palego L, Betti L, Miraglia F, Giannaccini G, Ceravolo R.

Brain Sci. 2018 Aug 26;8(9). pii: E161. doi: 10.3390/brainsci8090161.

Direct assessment of presynaptic modulation of cortico-striatal glutamate release in a Huntington's disease mouse model.

Koch ET, Woodard CL, Raymond LA.

J Neurophysiol. 2018 Oct 17. doi: 10.1152/jn.00638.2018. [Epub ahead of print]

Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.

Drombosky KW, Rode S, Kodali R, Jacob TC, Palladino MJ, Wetzel R.

Neurobiol Dis. 2018 Aug 29. pii: S0969-9961(18)30508-4. doi: 10.1016/j.nbd.2018.08.019. [Epub ahead of print]

Quality of life in Huntington's disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life.

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Sca

Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27317. [Epub ahead of print] Review.

Customized Dietary Intervention Avoids Unintentional Weight Loss and Modulates Circulating miRNAs Footprint in Huntington's Disease.

Aganzo M, Montojo MT, López de Las Hazas MC, Martínez-Descals A, Ricote-Vila M, Sanz R, González-Peralta I, Martín-Hernández R, de Dios O, Garcés C, Galdón A, Lorenzo Ó, Tomás-Zapico C, Dávalos A, Váz

Mol Nutr Food Res. 2018 Oct 25:e1800619. doi: 10.1002/mnfr.201800619. [Epub ahead of print]

Improvement of BDNF signalling by P42 peptide in Huntington's disease.

Couly S, Paucard A, Bonneaud N, Maurice T, Benigno L, Jourdan C, Cohen-Solal C, Vignes M, Maschat F.

Hum Mol Genet. 2018 Jun 1. doi: 10.1093/hmg/ddy207. [Epub ahead of print]

Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study.

Coppen EM, van der Grond J, Roos RAC.

J Clin Mov Disord. 2018 Mar 23;5:2. doi: 10.1186/s40734-018-0069-3. eCollection 2018.

Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats.

Danduga RCSR, Dondapati SR, Kola PK, Grace L, Tadigiri RVB, Kanakaraju VK.

Biomed Pharmacother. 2018 Sep;105:1254-1268. doi: 10.1016/j.biopha.2018.06.079. Epub 2018 Jun 22.

Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.

Liu SY, Yu XL, Zhu J, Liu XM, Zhang Y, Dong QX, Ma S, Liu RT.

Brain Res. 2018 Jun 11. pii: S0006-8993(18)30336-6. doi: 10.1016/j.brainres.2018.06.009. [Epub ahead of print]

Stem cell transplantation for Huntington's diseases.

Choi KA, Choi Y, Hong S.

Methods. 2018 Jan 15;133:104-112. doi: 10.1016/j.ymeth.2017.08.017. Epub 2017 Sep 1. Review.

Mouse model of chorea-acanthocytosis exhibits male infertility caused by impaired sperm motility as a result of ultrastructural morphological abnormalities in the mitochondrial sheath in the sperm midpiece.

Nagata O, Nakamura M, Sakimoto H, Urata Y, Sasaki N, Shiokawa N, Sano A.

Biochem Biophys Res Commun. 2018 Jun 21. pii: S0006-291X(18)31408-6. doi: 10.1016/j.bbrc.2018.06.096. [Epub ahead of print]

Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.

Boros FA, Klivényi P, Toldi J, Vécsei L.

Expert Opin Ther Targets. 2018 Nov 22:1-13. doi: 10.1080/14728222.2019.1549231. [Epub ahead of print]